This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Croton lechleri is a species of flowering plant in the spurge family, Euphorbiaceae, that is native to northwestern South America. It is commonly known as sangre de grado (sic, Peruvian Spanish), sangre de drago (Ecuadorian Spanish) or sangre de grada (sic, Bolivian Spanish). They refer to this tree's (and several related species') thick red latex. The latex has medicinal properties, and is used by local peoples as a liquid bandage, applied to seal wounds, as it dries quickly to form a protective skin-like barrier. Its use by native people has led to scientific study and observation of its in vitro antioxidant activity as well as both mutagenic and antimutagenic behavior. The latex also contains a number of chemicals, including taspine. Oligomeric proanthocyanidins, another kind of chemical contained in the latex, have been investigated for the treatment of HIV-associated diarrhea under the name crofelemer. In January 2013, crofelemer, under the trade name Mytesi, was approved by the FDA for the treatment of non-infectious diarrhea in HIV+ patients.
The General Principles of Software Validation (FDA 2002) defines verification as "Software verification provides objective evidence that the design outputs of a particular phase of the software development life cycle meet all of the specified requirements for that phase." It also defines Validation as "Confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses, and that the particular requirements implemented through software can be consistently fulfilled". The software validation guideline states: “The software development process should be sufficiently well planned, controlled, and documented to detect and correct unexpected results from software changes." Annex 11 states "The validation documentation and reports should cover the relevant steps of the life cycle." Weichel (2004) recently found that over twenty warning letters issued by the FDA to pharmaceutical companies specifically cited problems in Computer System Validation between 1997 and 2001. Probably the best known industry guidance available is the GAMP Guide, now in its fifth edition and known as GAMP5 published by ISPE (2008). This guidance gives practical advice on how to satisfy regulatory requirements.
=== 2019 recall of Ranitidine products === In 2019, Dr. Reddy's recalled all ranitidine products in the US market due to contamination with the carcinogen N-nitrosodimethylamine (NDMA). Months later, all brands of ranitidine were recalled and it was taken off the US market, as the carcinogen was an unavoidable byproduct.
Treponema pallidum, formerly known as Spirochaeta pallida, is a microaerophilic, gram-negative, spirochaete bacterium with subspecies that cause the diseases syphilis, bejel (also known as endemic syphilis), and yaws. It is known to be transmitted only among humans and baboons. T. pallidum can enter the host through mucosal membranes or open lesions in the skin and is primarily spread through sexual contact. It is a helically coiled microorganism usually 6–15 μm long and 0.1–0.2 μm wide. T. pallidum's lack of both a tricarboxylic acid cycle and processes for oxidative phosphorylation results in minimal metabolic activity. As a chemoorganoheterotroph, Treponema pallidum is an obligate parasite that acquires its glucose carbon source from its host. Glucose can be used not only as a primary carbon source but also in glycolytic mechanisms to generate ATP needed to power the bacterium given its minimal genome. The treponemes have cytoplasmic and outer membranes. Using light microscopy, treponemes are visible only by using dark-field illumination. T. pallidum consists of three subspecies, T. p. pallidum, T. p. endemicum, and T. p. pertenue, each of which has a distinct related disorder. The ability of T. pallidum to avoid host immune defenses has allowed for stealth pathogenicity. The unique outer membrane structure and minimal expression of surface proteins of T. pallidum has made vaccine development difficult. Treponema pallidum can be treated with high efficacy by antibiotics that inhibit bacterial cell wall synthesis such as the beta-lactam antimicrobial penicillin-G.
Sources: en.wikipedia.org
Commission B1: Thermodynamics and Transfer Processes The objectives of Commission B1 on Thermodynamics and Transfer Processes are to provide academic and industrial information and data, and to propose any solutions on thermodynamics and transfer processes. The Commission B1 has been extremely active in IIR Working Groups, sub-commissions, IIR conferences, co-sponsored conferences, and commission business meetings. As well as being involved in IIR Working Groups on the mitigation of direct emissions of greenhouse gases in refrigeration, the commission is equally involved in the Working Group on Life Cycle Climate Performance (LCCP) Evaluation. Active in IIR conferences and congresses, Commission B1 similarly organises workshops in various fields such as refrigerant charge reduction in refrigerating systems. Initiatives and opportunities, such as the phase-down of high-GWP refrigerants, energy-efficient buildings and cars, transport refrigeration, food preservation, the economic importance of the refrigeration sector, the involvement of the younger generation and identifying industrial needs are all at the heart of Commission B1.
On May 26, 2016, Green Berets supported about 80 soldiers of the Afghan 3rd Special Operations Battalion whose mission was to clear insurgents from Elbak, Kandahar province. The goal was to clear the road from Kandahar through Elbak to Tarin Kowt and allow an 800-man Afghan army convoy to deliver troops and supplies to Tarin Kowt. Green Berets called in three airstrikes by U.S. drones on Taliban insurgents near the landing zone, killing seven and wounding others. The mission had mixed results. The Taliban reoccupied the area and the convoy barely made any progress, however the operation interrupted the Taliban's nightly routine of bomb-planting. A week later, the Afghan commandos removed 18 booby-trap bombs from the road and made their way slowly through Elbak and further north. On August 23, a US soldier from A Company, 3rd battalion, 1st SFG, was killed by an IED while another was wounded along with six Afghans during a foot patrol near Lashkar Gah, Helmand Province. On October 4, 2016, a US soldier from B Company, 2nd Battalion, 10th SFG was killed by a roadside bomb blast in Achin, Nangarhar province. He was on a patrol with Afghan forces during an operation against ISIL-KP militants. This marked the first time a U.S. serviceman was killed in combat against IS militants in the country. On October 17, DEA agents, supported by a US Army Green Beret A-team and Afghan counter-narcotic units conducted a warranted search in a remote village in Farah province.
== Traditional uses == Puffballs have a long history of use in traditional medicine across the world. The dry, powdery spores were widely used as a styptic to stop bleeding and as a dressing for wounds, burns, and sores. This practice was common among Indigenous peoples of North America, who applied the spore powder directly to wounds, cuts, and nosebleeds, and also used it on the umbilical cords of newborns to aid clotting and prevent infection. This ethnomycological use was not confined to the Americas, with similar hemostatic applications being independently developed in Asia and Europe. Modern scientific analysis has lent support to these traditional practices, finding that puffball spores contain compounds with antimicrobial and antibacterial properties effective against some pathogens, and that they can promote fibrin formation.
== Description == Within a group of people, a command hierarchy defines who carry out orders based on group members' authority. In sociology, command hierarchy is seen as the most visible element of a "power network". In this model, social capital is viewed as being mobilized in response to orders that move through the hierarchy leading to the phrase "command and control".
=== Non-invasive imaging === A variety of Sendai virus constructs carrying reporter genes were developed for non-invasive imaging of the virus infection in animals. They allow to study dynamics of SeV spread and clearance. Some of these constructs were designed to deliver luciferase genes, some to deliver green fluorescent protein (GFP), others to deliver red fluorescent protein (RFP).
Sources: en.wikipedia.org
To determine causes of diseases, medical experts used the most common and widely accepted assumptions or symptoms of their times, a general principle of approach that persists in modern medicine. Modern medicine was particularly advanced by further developments of the microscope to analyze tissues, to which Rudolf Virchow gave a significant contribution, leading to a slew of research developments. By the late 1920s to early 1930s pathology was deemed a medical specialty. Combined with developments in the understanding of general physiology, by the beginning of the 20th century, the study of pathology had begun to split into a number of distinct fields, resulting in the development of a large number of modern specialties within pathology and related disciplines of diagnostic medicine.
Performance of the MasSpec Pen for ovarian cancer diagnosis was further evaluated in a report published in 2019. The authors analyzed 160 human ovarian tissue samples, including 78 normal ovary and 82 serous carcinomas, with the MasSpec Pen and developed classification models to discriminate between the normal and cancer samples. The model was able to distinguish between the normal and cancerous ovarian samples with 98.3%, 100.0%, and 92.3% overall accuracy on a training, validation, and test set of samples. Further, the report evaluated the ability of the MasSpec Pen system to distinguish ovarian cancer from fallopian tube and peritoneum tissue, two of the most common sites for ovarian cancer metastasis. Accuracies of 87.9% and 92.6% were achieved for the discrimination of cancer from fallopian tube and peritoneum tissues, respectively. The MasSpec Pen has also been implemented for the detection of pancreatic cancer during excision procedures. The MasSpec Pen was used on both ex vivo and in vivo tissue samples to discriminate between healthy pancreas and pancreatic tumor tissue. The device was also used to detect cancerous margins near adjacent structures of the pancreas such as the bile duct. The system was used in 18 pancreatic cancer surgeries and the data collected allowed the detection of cancerous tissue with high accuracy.
Methylestradiol, sold under the brand names Ginecosid, Ginecoside, Mediol, and Renodiol, is an estrogen medication which is used in the treatment of menopausal symptoms. It is formulated in combination with normethandrone, a progestin and androgen/anabolic steroid medication. Methylestradiol is taken by mouth. Side effects of methylestradiol include nausea, breast tension, edema, and breakthrough bleeding among others. It is an estrogen, or an agonist of the estrogen receptors, the biological target of estrogens like estradiol. Methylestradiol is or has been marketed in Brazil, Venezuela, and Indonesia. In addition to its use as a medication, methylestradiol has been studied for use as a radiopharmaceutical for the estrogen receptor.
In May 2017, Dynamic Technical Formulations voluntarily recalled all lots of Tri-Ton, a dietary supplement that the FDA tested and found to contain Enobosarm and andarine. In October 2018, UFC fighter Sean O'Malley tested positive for Enobosarm and was suspended by the Nevada State Athletic Commission and USADA for six months. O'Malley tested positive again on May 25, 2019 and was suspended for nine months by the same agencies. USADA determined that none of O'Malley's positive tests were consistent with intentional use and he was allowed to compete at UFC 248 as long as he kept his levels below the threshold of 100 ng/ml. On January 7, 2019, the College National Football Championship was played between University of Alabama and Clemson University. Prior to the College Football National Championship game, three Clemson players who were suspended — Dexter Lawrence, Braden Galloway and Zach Giellaall — tested positive for a substance known as enobosarm. On June 23, 2019 Clemson did not release enobosarm investigation findings, citing privacy law. In July 2019, National Football League player Taylor Lewan failed a drug test for Enobosarm, which Lewan claimed he ingested accidentally as an unlabeled ingredient in a supplement. On October 23, 2020, the Union Cycliste Internationale (UCI) announced that the Italian rider Matteo Spreafico has been notified of two adverse analytical findings (AAFs) for Enobosarm in two samples collected during the Giro d'Italia on 15–16 October 2020.
Kleptomania A psychiatric disorder characterized by recurrent urges to steal items not needed for personal use or value. Considered in neuropsychiatry as a type of impulse control disorder involving frontal lobe dysfunction. Klüver–Bucy syndrome A behavioral disorder caused by bilateral lesions of the amygdala and temporal lobes, resulting in hyperorality, hypersexuality, and emotional blunting. Knock-in A genetic technique where a gene is replaced or inserted at a specific locus, allowing researchers to study the function of specific mutations in neural systems. Knockout mouse A genetically engineered mouse in which one or more genes have been turned off through targeted mutation. Frequently used to study gene function in brain development and behavior. Korsakoff syndrome A chronic memory disorder caused by thiamine (vitamin B1) deficiency, most commonly due to chronic alcohol misuse. It involves degeneration of the mammillary bodies and medial thalamus. Krebs cycle (Citric acid cycle) A key metabolic pathway that provides energy to neurons. Although a general biology term, it is critical in neuroscience for understanding brain metabolism and mitochondrial function. Kymograph An old device used to record changes in physiological activity over time, such as muscle contractions or nerve responses. Historically significant in neuroscience research.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.